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FXRIt has been established that bile salts play a role in the regulation of hepatic lipid metabolism. Accordingly, overt
signs of steatosis have been observed in mice with reduced bile salt synthesis. The aim of this study was to
identify the mechanism of hepatic steatosis in mice with bile salt deﬁciency due to a liver speciﬁc disruption of
cytochrome P450 reductase.
In this study mice lacking hepatic cytochrome P450 reductase (Hrn) or wild type (WT) mice were fed a diet
supplemented with or without either 0.1% cholic acid (CA) or 0.025% obeticholic acid, a speciﬁc FXR-agonist.
Feeding a CA-supplemented diet resulted in a signiﬁcant decrease of plasma ALT in Hrnmice. Histologically, he-
patic steatosis ameliorated after CA feeding and this was conﬁrmed by reduced hepatic triglyceride content
(115.5 ± 7.3 mg/g liver and 47.9 ± 4.6 mg/g liver in control- and CA-fed Hrn mice, respectively). The target
genes of FXR-signaling were restored to normal levels in Hrnmice when fed cholic acid. VLDL secretion in both
control and CA-fed Hrn mice was reduced by 25% compared to that in WT mice. In order to gain insight in the
mechanism behind these bile salt effects, the FXR agonist also was administered for 3 weeks. This resulted in a
similar decrease in liver triglycerides, indicating that the effect seen in bile salt fedHrn animals is FXR dependent.
In conclusion, steatosis in Hrn mice is ameliorated when mice are fed bile salts. This effect is FXR dependent.
Triglyceride accumulation in Hrn liver may partly involve impaired VLDL secretion.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Bile salts play an important role in the absorption of lipids and fat
soluble vitamins in the intestine. Bile salts are synthesized in the liver
from cholesterol and this constitutes an important route by which cho-
lesterol is eliminated from the body. The ﬁrst enzymatic process in this
conversion is rate limited by cholesterol 7α-hydroxylase (CYP7a1)
[1,22]. The process of bile salt synthesis is tightly regulated via a nega-
tive feedback loop [5,12,14].When bile salt concentrations are high, nu-
clear receptor FXR will be activated and a cascade of genes, including
SHP and FGF19 in the ileum, is activated to reduce CYP7a1 activity [8].
Knockout mice for Cyp7a1 show signs of fatty liver [3]. Steatosis can
be caused by increased lipogenesis, increased uptake of fatty acids
from the blood, reduction of mitochondrial fatty acid oxidation and/or
the reduction of hepatic VLDL synthesis and secretion.d Intestinal Research, Academic
sterdam, The Netherlands.
ude Elferink).Near complete reduction of all hepatic cytochrome P450 enzyme ac-
tivity in mice (as is the case in mice with a gene disruption of hepatic
P450 reductase; Hrn mice) almost annihilates bile salt synthesis but
also results in steatosis [6]. This brings up the question whether this is
related to bile salt deﬁciency or whether this is related to the altered
lipid metabolism as described by Finn et al. [4].
It is known from literature that FXR not only plays a key role in the
negative feedback loop of bile salt synthesis, but also plays an important
role in the regulation of triglyceride and cholesterol homeostasis. Key
regulators in lipogenesis and in fatty acid oxidation such as FAS [15],
PPARα [20] and SREBP-1c [28] are regulated by FXR activation. It has
been suggested that lipogenesis and bile salt synthesis are linked pro-
cesses [2,15,20,28,29]. Apart from nuclear receptors such as FXR this
regulation may also partly be mediated via microRNAs. Li et al. [13] re-
cently showed that mice with increased bile salt synthesis (transgenic
overexpression of Cyp7a1) have increased Srebp2 expression with a
concomitant increase of miR 33a which is intronic in the Srebp gene.
In these mice Srebp1c is also slightly upregulated.
Since Hrnmice have strongly impaired bile salt synthesis [11] and
show steatosis [6], they are an attractive model to study the inﬂuence
of bile salts on lipogenesis and steatosis. Considering the close relation
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Fig. 1. Liver weight and plasma liver enzymes forWT andHrnmice.Micewere fed control
or 0.1% CA supplemented diet for 3 weeks. After the feeding period blood and livers were
collected. Panel A shows the liver weight as percentage of bodyweight ofWT (n= 5) and
Hrn mice (n = 4) fed a control diet, and WT (n = 7) and Hrn mice (n = 10) fed
CA-supplementeddiet. LW= liverweight, BW=bodyweight; panel B: plasmaALT levels
(all groups n = 10) and panel C: plasma AST levels (all groups n = 10). Open bars; WT,
closed bars; Hrn. * p N 0.05, ** p N 0.01, *** p N 0.001.
740 C. Kunne et al. / Biochimica et Biophysica Acta 1842 (2014) 739–746between bile salt homeostasis and lipid metabolism, we hypothesize
that the fatty liver of Hrnmice is related to bile salt deﬁciency induced
by Hrn deletion. We also hypothesize that the main regulatory factor
controlling all these processes is FXR.
2. Material and methods
2.1. Animals
Experiments were performed with age-matched 2–6 month old
male C57Bl/6 PORlox/lox (WT) and C57Bl/6 PORlox/lox + CREALB
(Hrn) mice. The mice were kept in a pathogen-free environment on a
controlled 12 h light–dark regime. As a control condition, the mice
were fed a puriﬁed semisynthetic diet (K4068.02; Arie Blok diervoeders,
Woerden, The Netherlands) for 5 weeks; the experimental groupswere
ﬁrst fed a control diet for 2 weeks followed by 3 weeks of this diet sup-
plemented with 0.1% cholic acid (CA) or 0.025% of the FXR agonist,
obeticholic acid (INT-747) ad libitum. After the feeding period mice
were sacriﬁced and blood, liver and ileum were harvested for further
analysis. The organ samples were, for one part, immediately frozen in
liquid nitrogen and then kept at−80 °C, for the other part ﬁxed in 4%
paraformaldehyde. The latter were stored in 70% ethanol after 24 h of
ﬁxation. All animal experiments were approved by the institutional an-
imal care and use committee of theAcademicMedical Center, University
of Amsterdam.
2.2. Plasma biochemistry
All plasma biochemistry e.g. alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) were performed by the routine labo-
ratory of clinical chemistry of the AMC.
2.3. Quantitative PCR analysis of gene expression
Liver and ileal tissue was snap frozen and stored at−80 °C. RNAwas
isolated using Trizol reagent (Invitrogen, The Netherlands). cDNA syn-
thesis was transcribed using locked oligo-dT primers and Superscript III
reverse transcriptase (Invitrogen, The Netherlands). Quantitative PCR
was performed using a Lightcycler 2.0 with the Fast Start DNAMasterPlus
SYBR Green I kit (Roche, The Netherlands). Speciﬁc primers (5′→ 3′)
prepared by Biolegio BV® (Nijmegen, The Netherlands) were used for
the measurement of expression levels, which were normalized by the
geometrical mean of housekeeping genes hypoxanthine-guanine
phosphoribosyltransferase (HPRT), 36B4 and ribosomal protein S in
liver tissue [21].
2.3.1. Histology
Liverswere ﬁxed in 4% paraformaldehyde solution and embedded in
parafﬁnwax, and 7-μmsectionswere stainedwithH&E or Sirius red. Oil
red O stainings were performed on frozen sections.
2.3.2. Liver triglycerides
Hepatic lipids were extracted by a chloroform/methanol extraction
protocol, adapted from Srivastava et al. [19]. Liver, and plasma triglycer-
ides were measured using a commercially available Trig/GB-kit (Roche,
The Netherlands).
2.4. Plasma VLDL measurement
After 2 weeks of control diet, the Hrn (n= 5) andWT (n= 5) mice
were fed for 3 weeks either the control or 0.1% CA supplemented diet.
On the last day of the experiment, overnight fasted mice were submit-
ted to puncture for blood collection 5 min before i.v. injection with
5 μL/g 10% tyloxapol (WR1339), in order to block lipoprotein lipase,
and blood was collected 30, 60, 90 and 180 min after injection. Triglyc-
eride levels weremeasured in plasma samples, following the techniquerecommended by themanufacturer of the triglyceride assay kit (Roche,
The Netherlands), at 490 nmusing an ELISA reader. Plasma triglycerides
increase over time and the slope is a measure for VLDL production.2.5. Protein expression by western blotting
The expression of scavenger receptor b1 (Sr-b1) and the regulatory
enzyme acetylCoA carboxylase-2 (Acc2) was measured by western
blotting according to Sambrook et al. [23]. Thirtymicrograms of proteins
obtained from hepatocyte membrane or supernatant, measured
by the Pierce bicinchoninic acid (BCA) method, was applied to
polyacrylamide-SDS gel. After electrophoresis the proteins were trans-
ferred to PVDF membrane for reacting with speciﬁc primary (1:2000)
and secondary (1:1000) antibodies. The proteins were observed
through the LumiAnalyst 3.1 program using Lumi-Imager F1 (Roche,
The Netherlands) equipment. Sr-b1 and Acc2 were normalized by
Atp1a1, used as a loading control.
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Fig. 3. Liver triglyceride content. Mice were fed control or 0.1% CA supplemented diet for
3 weeks. Lipids were extracted and triglycerides (TG) (A) and cholesterol (B) were
measured. Open bars; WT, closed bars; Hrn (control diet: WT n = 5 and Hrn n = 4;
CA-supplemented diet: WT n = 4 and Hrn n = 4). * p N 0.05, ** p N 0.01, *** p N 0.001.
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Data are given as means ± SEM unless indicated otherwise. Signiﬁ-
cance was tested by the use of the two-way ANOVA followed by
Student's t-test considering statistical signiﬁcance when p b 0.05.
3. Results
3.1. Liver weight and biochemical analysis
Macroscopically, livers of Hrnmice were big, pale and clearly fatty
compared to those of WT mice. In relation to body weight, the livers of
Hrnmice were bigger than those of WT mice. This difference in weight
did not change upon feeding a bile salt supplemented diet (Fig. 1A). Plas-
ma liver enzymesALT andASTwere increased inHrnmice on the control
diet compared to Wt mice. However, feeding a CA-supplemented diet
for 3 weeks resulted in a considerable decrease of AST and ALT in Hrn
mice towards levels seen in WT mice (Fig. 1B and C).
3.2. Hepatic fat is reduced in Hrn mice upon bile salt suppletion
Since hepatic fat was visibly increased, Oil red O stainings were
done.Hrnmice on the control diet displayedmoremacrovesicular stain-
ing for lipid droplets thanWTmice (Fig. 2A). Since bile salt supplemen-
tation for 3 weeks resulted in reduced levels of ALT and AST, we also
stained livers from mice that were fed a CA supplemented diet. Hrn
mice had strongly reduced staining of lipid droplets in the liver
(Fig. 2A and B).
To quantify the decrease of hepatic lipid droplets, liver triglycerides
(TG) were measured. Hepatic TG in Hrn mice were reduced from
115.5 ± 7.3 mg/g liver to 47.9 ± 4.6 mg/g liver upon cholate feeding,
whereas in WT controls the decrease was much smaller (resp. 39.6 ±
6.0 mg/g liver and 21.8 ± 1.2 mg/g liver) (Fig. 3A). Hepatic cholesterolA
WT control Hrn control
20x 20x
20x20x
WT 0.1% CA Hrn 0.1% CA
B
Fig. 2. Lipid staining in frozen liver sections. Mice were fed control or 0.1% CA supplemented diet for 3 weeks. Sectionswere stained with Oil red O. Panel A shows representative sections
from control fed WT (left) and Hrn (right) mice. Panel B shows representative sections from 0.1% CA fed WT (left) and Hrn (right) mice.
742 C. Kunne et al. / Biochimica et Biophysica Acta 1842 (2014) 739–746content was not signiﬁcantly different between all the groups (Fig. 3B),
although therewas a trend towards higher cholesterol inHrn compared
to WT which disappeared upon bile salt suppletion.
3.3. Hepatic gene expression in lipid metabolism
In order to ﬁnd the mechanisms responsible for the reduction of
steatosis observed in Hrn mice on the CA-supplemented diet, the
mRNA level of genes regulating the synthesis and oxidation of lipids
was investigated in hepatic and ileal tissues. The most evident differ-
ence in gene expression in Hrn was the induction of hepatic Cyp7a1
(Fig. 4A) which is an expected ﬁnding in view of the strongly reduced
bile salt pool. In linewith our previous observation that bile salt synthe-
sis ismore than ten-fold reduced inHrnmice [11], we found that the he-
patic nuclear receptor Shp was also strongly down-regulated in these
mice (Fig. 4B). When fed a CA-supplemented diet, both Cyp7a1 and
Shp expression normalized in Hrnmice (Fig. 4A and B). The expressionCyp7a1
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Fig. 4.Hepatic gene expression. Mice were fed control or 0.1% CA supplemented diet for
salt and fat metabolism and FXR target genes. Open bars, WT; closed bars, Hrn (control d
* p N 0.05, ** p N 0.01, *** p N 0.001.of Abcg5 was reduced in Hrn mice fed a control diet but was restored
to (increased) control levels when fed a CA-supplemented diet
(Fig. 4C). Abcg8 expression was unaffected in Hrn mice on a control
diet and, like in WT mice, was 3-fold increased upon CA feeding
(Fig. 4D). A similar increase was seen for Aco and Sr-b1 (Table 1). Com-
pared toWT, Srebp-1cwasmildly elevated inHrn liver, andwas induced
to a higher extent upon CA feeding (Fig. 4E). Furthermore, HmgCoA re-
ductasewas unaffected in control-fed mice and was decreased only in
Hrnmice when fed a cholic acid diet (Fig. 4F), suggesting reduced cho-
lesterol synthesis. Lfabp, Acc1, Cd36 and Fas, showed no signiﬁcant dif-
ferences between diet or genotype (Table 1). We also measured a few
target genes that are involved in fatty acid oxidation. Cpt1a is localized
in the innermitochondrialmembrane and responsible for the formation
of acyl-CoA for fatty acid oxidation. Neither genotype nor diet had a sig-
niﬁcant effect on Cpt1a expression. Similarly, under these conditions
there was no signiﬁcant change in the expression of Ces1, involved in
triglyceride hydrolysis (Table 1).Shp
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3 weeks. Panels A–J represent relative expression of hepatic genes involved in bile
iet: WT n = 12 and Hrn n = 7; CA-supplemented diet: WT n = 12 and Hrn n = 12).
Table 1
Hepatic expression of genes involved in fatty acid metabolism.
Gene evaluated Control diet 0.1% CA Statistic signiﬁcance
WT (n = 12) Hrn (n = 7) WT (n = 12) Hrn (n = 12)
Lfabp 180 ± 9 165 ± 27 179 ± 14 154 ± 13 n.s.
Aco 0.035 ± 0.002 $ 0.048 ± 0.008 # 0.111 ± 0.023 $ 0.091 ± 0.008 # #: p b 0.01
$: p b 0.01
Acc1 0.012 ± 0.001 0.009 ± 0.001 0.010 ± 0.001 0.010 ± 0.001 n.s.
Cd36 0.387 ± 0.053 0.584 ± 0.109 0.527 ± 0.078 0.749 ± 0.104 n.s.
Fas 0.0007 ± 0.0002 0.0003 ± 0.0001 0.0007 ± 0.0002 0.0010 ± 0.0004 n.s.
Sr-b1 0.002 ± 0.0003 $ 0.001 ± 0.0003 # 0.004 ± 0.0007 $ 0.003 ± 0.0005 # #: p b 0.05
$: p b 0.05
Cpt1a 0.27 + 0.072 0.46 + 0.097 0.30 + 0.19 0.49 + 0.33 n.s.
Ces-1 0.15 + 0.052 0.18 + 0.042 0.19 + 0.071 0.23 + 0.18 n.s.
Mice were fed control or 0.1% CA supplemented diet for 3 weeks. The results are presented as the relative expression of the genes normalized for HPRT/RS expression. Signiﬁcance
symbols represent: n.s. = not signiﬁcant; # = CA versus CTRL diet in Hrn; $ = CA versus CTRL diet in WT (control diet WT n = 12 and Hrn n = 7; CA-supplemented diet WT n = 12
and Hrn n = 12).
743C. Kunne et al. / Biochimica et Biophysica Acta 1842 (2014) 739–7463.4. Ileal gene expression in metabolism
As expected, ileal gene expression showed major differences in
Ibabp, Fgf15 and Shp between WT and Hrn mice on the control diet
which all normalized in Hrnmice upon CA feeding (Table 2). Whereas
Fxrα and Abcg5 were induced in CA-fed WT mice, this was not the
case in CA-fed Hrnmice.
3.5. SR-B1 and ACC2 in hepatic fat metabolism and transport
Next, the expression levels of proteins involved in lipid metabolism
and transport were investigated. SR-B1 facilitates the uptake of choles-
terol fromhigh-density lipoproteins into the liver. The expression of this
transporter was not affected by diet or genotype (Fig. 5A), which was
consistentwith unaffected ileal Sr-b1mRNA levels (Fig. 5B). The expres-
sion levels of hepatic ACC2 and phosphorylated-ACC2 were also
checked. The function of ACC2 is to providemalonyl-CoA for the biosyn-
thesis of fatty acids. However, no signiﬁcant difference was observed in
the ratio P-ACC2/total ACC2 betweenWT andHrnmice on both the con-
trol and 0.1% CA supplemented diets (Fig. 5C).
3.6. VLDL excretion in Hrn liver
Since a CA-supplemented diet reduced the hepatic lipid content in
Hrnmice, VLDL secretion was measured in time. At the start of the ex-
periment, fasted plasma triglycerides were reduced by about 50% in
control-fedHrnmice although thiswas not signiﬁcant. Plasma triglycer-
ide levels were comparable in CA-fed WT and Hrn mice (Fig. 6A).Table 2
Ileal expression of genes involved in bile salt metabolism.
Gene evaluated Control diet
WT (n = 7) Hrn (n = 4)
Abcg5 1.00 ± 0.36 $ 1.65 ± 1.58
Ibabp 1.00 ± 0.29 $* 0.41 ± 0.24 #*
Fxra 1.00 ± 0.54 $ 1.00 ± 1.07
Fgf15 1.00 ± 0.48 $* 0.11 ± 0.09 #*
Shp 1.00 ± 0.70 $* 0.29 ± 0.27 #*
Mice were fed control or 0.1% CA supplemented diet for 3 weeks. The results are presented as
mice set to 1. Signiﬁcance symbols represent: # = CA versus CTRL diet in Hrn; $ = CA versus
fed Hrn (WT n = 5; Hrn n = 4).Compared to control-fed WT mice, VLDL secretion was mildly, though
not signiﬁcantly, reduced in control-fed Hrnmice (Fig. 6B). CA-feeding
resulted in a slight increase in VLDL secretion in WT mice, whereas
this was not the case in Hrn mice. As a consequence VLDL secretion
was signiﬁcantly reduced in CA-fed Hrn mice compared to WT under
cholate-supplemented conditions. Upon feeding of the FXR-agonist
obeticholic acid a similar difference betweenWT and Hrnmice was ob-
served but this was not signiﬁcant (p = 0.09) (Fig. 6B).
3.7. Effect of the FXR agonist obeticholic acid
To test whether the CA-induced reduction of hepatic fatwasmediat-
ed via FXR signaling, the mice were also fed with the FXR agonist
obeticholic acid (INT747) for 3 weeks. Obeticholic acid had the same re-
ducing effect on hepatic triglyceride content as CA feeding (Fig. 7) indi-
cating a role for FXR in the reduction of hepatic fat accumulation.
4. Discussion
This study shows the effects of bile salt supplementation on liver
steatosis in amousemodel with impaired bile salt synthesis, the hepatic
reductase null (Hrn) mouse. Bile salt and lipid metabolism are tightly
regulated and closely linked. Bile salt synthesis is regulated by a nega-
tive feedback loop in a FXR dependent manner. In short, CYP7a1 tran-
scription depends mainly on ileal FXR activation and subsequent
induction of SHP and FGF19 release which signals to the liver through
activation of the FGFR4 receptor present on the basolateral membranes
of hepatocytes [8]. However, bile salt-dependent FXR signaling also
plays a key role in lipid metabolism. It has been reported that FXR0.1% CA Statistic signiﬁcance
WT (n = 5) Hrn (n = 5)
3.27 ± 0.83 $,& 1.27 ± 1.06 & &: p b 0.05
$: p b 0.001
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*: p b 0.01
2.01 ± 0.80 &$ 0.74 ± 0.17 & &: p b 0.05
$: p b 0.05
2.78 ± 1.89 $ 2.78 ± 0.77 # #: p b 0.0001
$: p = 0.07
*: p b 0.01
9.02 ± 7.28 $ 7.77 ± 1.86 # #: p b 0.0001
$: p b 0.05
*: p = 0.07
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SREBP-1c expression [28]. SREBP-1c is known as a major player in
lipid homeostasis [28].
We and others [6] observed that Hrnmice with a low bile salt pool
size have a characteristic fatty liver, i.e. high hepatic triglycerides. An-
other model with a low bile salt pool size is the Cyp7a1 knockout
mouse, but its phenotype is so severe that without feeding bile salts,
these animals die [9]. In this model, liver histology was normal when
mice were fed cholic acid. In a more recent publication [3] the same
Cyp7a1 knockout mice were purchased from JAX labs and these
displayed a different phenotype, although they were initially generated
from the same strain. Although the cause of this difference in phenotype
has not been sorted out these JAX-generated Cyp7a1 knockout mouse
did not show lethality, but had hypercholesterolemia and displayed a
fatty liver.
The KK-Aγmouse, which is a model with increased obesity and fatty
liver but normal bile salt levels, shows diminished hepatic fat uponcholic acid feeding. Fxr−/− mice have increased hepatic triglycerides
[24] but have an 8-fold increased plasma bile salt pool size on a control
diet, due to lack of Cyp7a1 responsiveness. Shp expression in Fxr−/−
mice is low [24], which is in line with the FXR–SHP–SREBP-1c pathway
being important in the regulation of hepatic triglyceride content [28]. In
745C. Kunne et al. / Biochimica et Biophysica Acta 1842 (2014) 739–746summary, all these models indicate a direct role for bile salt activated
Fxr in the regulation of lipid metabolism.
Restoring the bile salt pool in Hrnmice ameliorates plasma liver en-
zyme levels and dramatically reduces hepatic triglyceride content. As
expected, Shp expression, which was exceedingly low in Hrnmice, in-
creased after BS supplementation. When Shp−/−mice were fed either
CA or a speciﬁc FXR agonist, this did not result in a signiﬁcant decrease
in hepatic triglycerides [27,28], whereas this did happen inWTmice, in-
dicating that the bile salt-mediated reduction of triglycerides depends
on SHP signaling. Our observations are in line with those in Fxr−/−
and Shp−/−mice in that liver triglyceride content seems to be regulated
(in part) by the bile salt–FXR–SHP axis. When we challenged Hrnmice
with a FXR agonist, we observed the same decrease in hepatic triglycer-
ides as observed with CA-supplementation of the diets, which further
strengthens the conclusion that hepatic triglyceride reduction in Hrn
mice is FXR-dependent. In control-fed Hrnmice, ileal Fgf15 expression
was decreased, whereas Fgf15 expression was induced after feeding a
CA-supplemented diet. A study in Fxr−/−mice revealed that treatment
with human FGF19, the human ortholog of mouse Fgf15, ameliorated
hepatic triglyceride content [17]. This effect was attributed, at least
partly, to the FGF19-mediated induction of Shp and subsequent de-
crease in Srebp-1c expression. In contrast, we observed an increased ex-
pression of Srebp-1c in control-fed Hrn mice (as compared to wild
types), which was even further induced when the bile salt pool was re-
stored. Itmust be stressed in this context thatWatanabe et al. [28] found
themajor effect of Srebp-1c only on day 1 after bile salt feeding; Srebp-1c
expression diminished within a week, indicating that the Fxr-mediated
downregulation of Srebp-1cmaybe temporary only. In our experiments,
the bile salt-supplemented dietwas administered for 3 weeks; as a con-
sequence, our experiments do not reveal short term effects on Srebp-1c
anddownstreamgenes. In addition, given the slowdisappearance of he-
patic triglycerides, changes in the expression of these genes may be too
small to be found in this experimental set-up. Furthermore, bile salt was
administered via the diet and not by oral gavage which causes a more
continuous, mild but chronic activation of FXR. Hence, the mechanism
of long term reduction of hepatic triglycerides upon chronic FXR signal-
ing remains to be explained.
A study in Shp−/−mice showed (relatively small) induction of Acc
and Fas expression, which suggested that hepatic triglyceride accumu-
lationwas caused by increased fatty acid synthesis [10].We foundno in-
crease in the expression of these genes upon bile salt feeding of Hrn
mice. It must be stressed, however, that the loss of hepatic triglycerides
occurred quite slow and, as described above, FXR signaling in ourmodel
may be mild with concurrent small changes in the expression of genes
involved in fatty acid synthesis, which do not reach signiﬁcance in he-
patic tissue. Indeed, in contrast to Fxr−/− and Shp−/− mice, in which
FXR signaling is completely abrogated, Hrnmice have residual FXR sig-
naling.Hrnmice still have about 8% of normal bile salt synthetic capacity
and, due to the efﬁcient reabsorption of bile salts in the intestine, the
bile salt pool is reduced to about 30% of normal [11]. Hence, FXR signal-
ing will not be entirely eliminated. Nevertheless, Shp expression in the
ileum is reduced to 29% of that in wild type mice (Table 2), indicating
that, although FXR signaling is still intact, it functions at a low level.
The reduction in hepatic triglycerides by bile salt feeding inHrnmice
may be mediated via Fxr activation or Tgr5 signaling or both. Both re-
ceptors are expected to be more activated in these animals upon bile
salt feeding [7,25,26]. However, we observed a similar effect on liver tri-
glycerides by chronic administration of a diet containing the Fxr-speciﬁc
agonist 0.025% obeticholic acid, suggesting that this effect is mainlyme-
diated through Fxr. Inwild typemicewe have observed that this dose of
obeticholic acid does not induce DIO2 expression in brown adipose tis-
sue whereas administration of the Tgr5-speciﬁc agonist does (Oliveira
et al. unpublished observations). Although this suggests that the lipid-
reducing effect may be mainly mediated by Fxr, we cannot exclude
the realistic possibility that this dose of obeticholic acid activates Tgr5
in a bile salt-deﬁcient model such as the Hrnmouse. If this is the case,increased energy expenditure might be the underlying mechanism
[7,25,26].
Our results revealed a 24% decrease in VLDL secretion in both
control- and CA-fed Hrnmice compared to WT. This observation devi-
ates from other mouse models with increased hepatic triglycerides.
For instance KK-Aγ mice, which have a normal bile salt pool but high
liver triglyceride levels, display a decrease in VLDL secretion when fed
0.5% cholic acid or GW4064 for a week [28]. Although impaired VLDL
excretion in Hrn mice may contribute to liver steatosis in control-fed
mice, it is obviously not important in the amelioration of steatosis ob-
served after activation of FXR signaling, as no increase in hepatic VLDL
secretion was observed upon cholate feeding.
It must bementioned here that amajor difference betweenHrnmice
and othermousemodelswith increased hepatic triglycerides is thatHrn
micehave lowplasma triglyceride levels (rather than the high levels ob-
served in other models). As discussed above, Acc and Fas expression in
Hrn mice were unaffected. Although ACC and FAS are the only route
for the synthesis of fatty acids [16], this lack of expression differences
is also seen in a previous study with Hrnmice [18]. In addition, we did
not observe a reduction of Fas expression upon bile salt feeding (neither
in WT nor in Hrnmice).
In conclusion, we show here that steatosis in Hrnmice is caused by
the reduction in the bile salt pool as restoration of the bile salt pool
leads to a clear reduction in hepatic triglycerides. This reducing effect
of bile salts is mediated through FXR, because the administration of an
artiﬁcial FXR agonist has the same effect. The signaling pathway
through which this is brought about remains to be elucidated.Acknowledgements
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